KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cash from Financing Activities (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Cash from Financing Activities data on record, last reported at $75.4 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 1011.66% year-over-year to $75.4 million; the TTM value through Dec 2025 reached -$873.4 million, down 4357.07%, while the annual FY2025 figure was -$873.4 million, 4357.07% down from the prior year.
  • Cash from Financing Activities reached $75.4 million in Q4 2025 per JAZZ's latest filing, up from -$10.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $4.7 billion in Q2 2021 and bottomed at -$813.5 million in Q1 2025.
  • Average Cash from Financing Activities over 5 years is $114.1 million, with a median of -$67.5 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: tumbled 1953.24% in 2021, then surged 1011.66% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at -$246.6 million in 2021, then surged by 107.95% to $19.6 million in 2022, then tumbled by 611.87% to -$100.3 million in 2023, then soared by 91.75% to -$8.3 million in 2024, then soared by 1011.66% to $75.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $75.4 million in Q4 2025, -$10.8 million in Q3 2025, and -$124.5 million in Q2 2025.